TrialThe Lancet. Oncology2022

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.

Kim A Reiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.